News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Intercept Pharmaceuticals (ICPT) Expands Its Board Of Directors With Appointments Of Sanj K. Patel And Glenn Sblendorio


2/18/2014 9:18:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Intercept or the Company) (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced the appointment of Sanj K. Patel and Glenn Sblendorio to the Company's Board of Directors, effective immediately. Patel is currently the President and Chief Executive Officer of Synageva Biopharma Corp. (Nasdaq:GEVA) and Sblendorio is the President and Chief Financial Officer of The Medicines Company (Nasdaq:MDCO). With these additions, Intercept's Board of Directors is now comprised of nine directors.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES